Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering from rare diseases, while emphasizing the importance of an adequate rare disease framework to streamline this process in the future.
With the initiation of a study on how to implement a national pharmacare program, we are hopeful that this may represent an opportunity to finally have the rare disease community acknowledged and cared for more effectively
